Richmond Hyperbaric Health Center


Research on Diabetic Wounds

Diabetes Spectrum
Volume 10 Number 2, 1997, Pages 118-123
The Adjunctive Role of Hyperbaric Oxygen Therapy in the Treatment of Lower Extremity Wounds in Patients With Diabetes
Jeffrey A. Stone, DO, MPH,
and Paul Cianci, MD, FACP

In Brief
Diabetic foot wounds are one of the major complications of diabetes, resulting in substantial morbidity and mortality. One mode of therapy is hyperbaric oxygen therapy (HBO). This therapy is designed to increase oxygen delivery to local ischemic tissue and, by a variety of primary and secondary mechanisms, to facilitate wound healing in the high-risk foot. This article reviews the adjunctive benefits of HBO treatments in the diabetic wound.

Diabetes mellitus is the seventh leading cause of death in the United States and is widely prevalent in American society, affecting nearly 16 million people, or 6% of the U.S. adult population.1 Moreover, it is estimated that 7.2% of all hospitalizations in the United States involve diabetes, with more than 20% of these because of peripheral vascular disease and its related tissue damage in the lower extremities.

Nearly 50% of all nontraumatic lower extremity amputations performed in the United States are due to diabetes, with an annual incidence of 37–137 per 10,000 patients with this disease.1 Of these amputations, 9% are of a foot, 31% are of the lower leg, and 30% are at or above the knee.4 Ipsilateral higher amputations occur in 22% of cases. Contralateral amputations occur at a rate of 10% per year. After 5 years, amputees with diabetes have a 50% chance of bilateral amputation, often due to increased wear on the remaining limb. At any given time, perhaps 1 million patients with diabetes suffer from lower extremity ulcers. Wounds of the lower extremities are thus one of the major complications of diabetes, resulting in substantial morbidity and mortality.

The personal and economic costs of this problem are staggering. The cost of a primary amputation in 1986 dollars was reported to be more than $40,000.5 Current Medicare reimbursement for primary amputation is approximately $10,000.6 Sixty-eight percent of elderly amputees will be alive after 4 years, and only 40–50% will be successfully rehabilitated7,8 The length of hospital stay for primary amputation varies widely but has been reported to range from 22 to 40 days.3,9 Six to nine months may be necessary to maximize walking ability.10 Rehabilita-tion costs can add an additional $40,000–50,000.11 The total cost of amputation due to diabetes in the United States is nearly $1.5 billion per year.11 Readmission within 2 years for stump modification or re-amputation may represent an additional $1 billion expenditure.11

Primary amputation is far from an expeditious solution to the problem of foot wounds, particularly in patients with diabetes. The U.S. Department of Health has set a goal of reducing the amputation rate among patients with diabetes by 40% by 2000.12 Any treatment modality that would substantially reduce the morbidity of diabetic lower extremity wounds would have a profound effect on health-care costs. An aggressive, multidisciplinary team approach to diabetic foot management, in which patients are seen by appropriate specialists and undergo aggressive revascularization when indicated, has resulted in improved salvage and a significant cost benefit.11,13

Pathophysiology of Diabetic Foot Wounds
The diabetic foot is characterized by sensorimotor and autonomic neuropathies that lead to alteration of pressure distribution, foot deformities, and ulceration. The classical mal perforans ulcer is caused by loss of sensation and painless trauma. This can occur in the absence of ischemia and frequently heals with conservative measures, such as aggressive wound management and unweighting. Primary management is directed to patient education and foot care. Autonomic neuropathy may cause alterations in blood flow, resulting in islands of cutaneous ischemia.14

In patients with large-vessel obstruction, the mechanism of wound development is clear, and only the restoration of pulsatile blood flow will allow adequate healing. However, some patients with diabetes who have large-vessel perfusion and palpable pulses will still develop wounds that appear to be hypoxic/ischemic and will fail to heal.15,16 In these cases, the mechanism of wound development is less clear.

Even in the presence of palpable pulses, patients with diabetes can have areas of low flow and hypoxia in their feet and ankles. Contributing factors may include increased blood viscosity, increased platelet aggregation, and accelerated capillary endothelial growth.17-19 Capillary wall hyalinization can lead to capillary obstruction,20,21 and capillary hyperperfusion and vasodilatation can lead to injury via subendothelial deposition of macromolecules.19 Additionally, patients with diabetes respond to local tissue stresses through thrombosis and necrosis, as opposed to the inflammatory response that occurs in the nondiabetic population.22 Regardless of the mechanism involved, the net result is focal hypoxia that can involve regions of the ankle, foot, or toes.

Investigators believe that tight control of blood glucose concentration may slow or even reverse this pathological process, and periodic elevation of tissue oxygen tensions can also favorably influence this process. Surgical revascularization, particularly with in situ vein grafts, can frequently provide the necessary substrate for wound healing. However, in some cases, wound-healing failure occurs despite restored circulation. This suggests a problem with the wound-healing process itself, and indeed, defective wound healing has been demonstrated to be a major factor in the nonhealing diabetic ulcer.23

The Wound-Healing Process
The wound-healing process is a complicated one and is initiated by a complex series of events that include chemoattraction, growth-factor pathways, complement generation, and the energy-poor environments created by low oxygen tensions, low pH, and high lactate concentrations.24 Macrophages attracted to such environments release lactate aerobically, as well as anaerobically, and generate potent growth factors, resulting in brisk angiogenesis and multiplication of fibroblasts at wound margins. These events can take place in a low-oxygen environment. However, the modification of collagen by fibroblasts so that it can be polymerized and secreted into the extracellular space can be accomplished only when oxygen is present at high partial pressures. Therefore, collagen is deposited most rapidly when both lactate and oxygen concentrations are high. The need for oxygen persists well into the healing process, since new collagen must be deposited as old collagen is lysed. Production and remodeling must be in balance if wounds are to maintain tensile strength.

The mechanisms of oxygen enhancement of wound healing involve the hydroxylation of proline and lysine residues in procollagen. As mentioned above, these hydroxylation processes are necessary for polymerization and cross-linkage of procollagen strands and the transport of collagen molecules to the extracellular space. This process proceeds at one-half maximal rate at a PO2 (partial pressure of oxygen) of 20 mmHg and at 90% maximal rate at 200 mmHg.25 Thus, collagen deposition, the process that fills tissue defects and supports new blood vessels, proceeds in proportion to tissue oxygen levels.26 Cell replication also requires oxygen. Fibroblasts and vascular endothelial cells replicate most rapidly at a PO2 of 40 mmHg; epidermal cells may replicate best at 700 mmHg.27

Leukocytes kill most effectively when supplied with abundant oxygen,28 as their most effective killing is accomplished through the oxidative pathway. This mechanism is most efficient in high oxygen concentrations and fails rapidly as tissue oxygen tensions fall below 30–40 mmHg. Therefore, susceptibility to infection increases as tissue oxygen tensions decrease. Accordingly, wounds of the extremities are often infected, while infections are rare in those tissues that have higher flow and higher tissue oxygen tensions, such as in the face, tongue, and anal area. Similarly, well perfused and oxygenated flaps are resistant to infection and infectious gangrene, whereas random flaps, which have low oxygen tensions in their distal portions (analogous to the situation noted in the diabetic foot), are susceptible to infection and suffer a high degree of infectious necrosis.29-32 Oxidative killing is an important aspect of wound healing and is additive to the effect of appropriate antibiotics.33,34 Periodic oxygen administration to elevate PO2 above 100 mmHg enhances this process.

Angiogenesis is a fundamental requirement of healing, and the observations of Rohr and associates demonstrate the importance of oxygen in this process and are compatible with clinical observations of accelerated angiogenesis using oxygen at pressure.35 Angiogenesis occurs most rapidly when it proceeds from a high oxygen tension to a low one and from a low-lactate environment to a high one.24,36 The data of Marx and associates36 and Knighton and associates24 suggest that angiogenesis is proportional to the gradient of PO2 from capillary to wound space (i.e., a high tissue oxygen tension at the periphery of a wound and a low tissue oxygen tension at its center enhances angiogenesis). Therefore, restoration of PO2 to normal or supranormal levels enhances not only epithelialization, fibroplasia, collagen deposition, and bacterial killing, but also capillary proliferation and advancement into the wound space.

Principles of Hyperbaric Oxygen Therapy
The Undersea and Hyperbaric Medical Society, an international scientific organization and the leading authority for diving and hyperbaric medicine in the United States, defines hyperbaric oxygen therapy (HBO) as the intermittent administration of 100% oxygen in-haled at a pressure greater than sea level. (Topical oxygen therapy rendered in small limb-encasing devices is not considered HBO and has been demonstrated to be ineffective. It may, in fact, decrease oxygen delivery to affected limbs.37,38)

HBO is not new, having been used since 1943.39 Modern therapy dates to the early 1960s, when Dutch investigators demonstrated the efficacy of HBO in gas gangrene and anemic states.40,41 HBO is presently used as primary treatment for decompression illness (the bends), air embolisms, and severe carbon monoxide poisoning.42-44 Adjunc-tive indications include clostridial myonecrosis, crush injury and traumatic ischemias, enhancement of healing in selected problem wounds, necrotizing soft tissue infections, chronic refractory osteomyelitis, radiation damage to soft or hard tissue, compromised skin grafts or flaps, and thermal burns. All of these conditions share a common pathophysiology of local or focal hypoxia.36,45-66

HBO is designed to increase oxygen delivery to local ischemic tissue and, by a variety of primary and secondary mechanisms, to facilitate wound healing. It is a physiological process, in which a patient breathes 100% oxygen intermittently while the pressure of the external environment is increased to a greater-than-normal-sea-level pressure, usually 2.0–2.4 atmospheres absolute (ATA) or 33–45 feet of sea water (fsw). HBO may be implemented in a walk-in (multiplace) chamber, compressed to depth with air while the patient breathes 100% oxygen with a head tent, face mask, or endotracheal tube, or, alternatively, the patient may be treated in a one-person (monoplace) chamber pressurized to depth with oxygen. In either case, the arterial partial pressure of oxygen will approach 1,500 mmHg at the pressure equivalent of 33 fsw (10 m, or 2 ATA).

At normal atmospheric pressures, most of the oxygen in blood is carried by hemoglobin, with minimal additional oxygen dissolved in the plasma. By giving high concentrations of oxygen under increased pressure (2.0– 2.4 ATA), the dissolved oxygen in the blood can be significantly increased, resulting in an ~30% increase in oxygen-carrying capacity. These levels of dissolved oxygen have been shown to maintain life in the absence of hemoglobin.40 At a standard treatment pressure of 2.4 ATA, an arterial PO2 of 1500 mmHg can be achieved, which increases the driving pressure for diffusion of oxygen into the tissue and increases the diffusion distance by three- to fourfold.

HBO protocols vary depending on the severity of the situation. In the absence of infection, HBO once per day at 2.0–2.4 ATA for 90–120 minutes is sufficient to stimulate wound healing. In the presence of infection or a high risk of limb loss, treatment twice per day is recommended. Even though treatment sessions are relatively brief, oxygen tensions may remain elevated in subcutaneous tissue for several hours after exposure.67-69

By increasing tissue oxygen levels, HBO can attack the deleterious effects that hypoxia has on wound healing. The exact mechanism by which this is accomplished is not yet fully understood. However, there is evidence that suggests that HBO stimulates angiogenesis. Sheffield has demonstrated improvement in capillaries, measuring transcutaneous oxygen over healing tissue in the diabetic foot, and has clearly documented the slow improvement in blood flow over the first 3 weeks of HBO, as evidenced by rising tissue oxygen tensions.70 This is particularly true during HBO sessions. Marx has shown similar changes in ischemic irradiated tissue.36

Studies Investigating theEfficacy of HBO
Numerous retrospective studies have shown the efficacy of HBO. Davis reviewed a clinical series of 168 patients with compromised refractory diabetic foot wounds treated over a 7-year period.71 Utilizing the parameter of limb salvage, a success rate of 70% was obtained. Thirty percent failed to respond and required amputation above or below the knee. Failures were most common in older individuals without palpable pedal pulses and with large-vessel occlusion at or above the ankle diagnosed by angiography. Cianci treated 19 patients with diabetes in a subset of 39 lower extremity lesions in 1988, with a salvage rate of 89%.11 Forty-two percent of these patients had undergone successful revascularization and were referred because of persistent infection or nonhealing wounds. Salvage was defined as bipedal ambulation if two limbs were originally present and intact wound coverage remaining for at least 1 year. HBO costs were $12,668 and were reflected in total hospital charges of $34,370, with an average length of stay of 35 days.

More recently, another series of 41 patients with diabetes, who averaged 63 years in age, was analyzed.72 Thirty-nine patients (97%) were suffering limb-threatening lesions. Fifty-five percent of the patients had undergone revascularization. An average Wagner score of 4, indicating gangrene of the toes or forefoot, was obtained. Thirty-one patients (78%) had their lower extremities salvaged. HBO charges in this series were $15,900, total hospital charges were $32,000, and the average length of stay was 27 days, which compare favorably with the cost of primary amputation.

Avoidance of rehabilitation costs and the additional savings involved in prevention of re-amputation or stump revision has been an additional benefit. The follow-up of these patients over 1-6 years (average of 30 months) has shown a 92% durability; that is, ambulation without further lesions or problems. Two of the patients have suffered below-the-knee amputations.

In 1992, Oriani reported a 10-year experience that showed 80% salvage in a group that received HBO versus 40% in controls (P < 0.001).73 Initial treatment of 15 sessions and reevaluation was recommended, as significant improvement in wound healing should be apparent at that time. If improvement was noted, treatment was continued for an additional 10 sessions. If absent, HBO was discontinued. Gismondi has noted the importance of careful, aggressive debridement and meticulous wound care in reducing hospital stay, the number of HBO treatments, and ultimately, cost of care.74

In 1993–94, a pilot study was undertaken to examine the results of hyperbaric oxygen therapy in patients with diabetes seen at our centers. Data were collected in a retrospective manner utilizing 1,633 consecutive patients who were treated in our Dallas clinics over a 33-month period (March 1992 through November 1994). Five hundred and one patients (31%) presenting with diabetes and ischemic wounds were identified by diagnosis codes and confirmed by chart review. Patients were grouped by treatment modality: hyperbaric oxygen therapy (n = 119) versus conservative treatment alone (n = 382), which was administered according to the clinical judgment of the treating physician. Limb salvage (defined as bipedal ambulation if two limbs were present) was used as the endpoint for the study.

Hyperbaric treatment consisted of oxygen therapy delivered at an individualized rate, duration, and ATA for each patient. Complete follow-up was available on 73% (87 of 119) of the patients receiving hyperbaric oxygen. Some patients were referred from outside centers, and, therefore, their records were unavailable for review (n = 32).

Conservative treatment was based on the standard of care and individualized to include, if necessary: revascularization, dietary modification, smoking cessation, antibiotics, behavioral modification, wound debridement, glycemic control, and offloading.75 Patients referred for HBO had larger wounds (mean ± SE area: 2,533 ± 987 vs. 1,199 ± 61 mm3, P = 0.18), more wounds per patient (3.8 vs. 2.4, P < 0.0001), and a greater percentage recommended for amputation (31% vs. 19%, P = 0.002). Despite having the more serious wounds, the limb salvage rate was greater in the HBO patients (72% vs. 53%, P < 0.002).

The results of multiple other retrospective studies involving approximately 500 patients have been consistent and indicate a 70–90% success rate in patients who had been refractory to other modes of therapy, with success defined as the avoidance of amputation and, in many cases, complete wound healing.76-79

Baroni and associates prospectively treated 28 patients, 18 of whom received HBO.80 Unfortunately, the patients were not randomized. They were placed in the control group if they had claustrophobia, ischemic heart disease, paresthesia, or were felt to be unmotivated. All patients received daily debridement of ulcers to bleeding tissue with removal of necrotic tissue. Physicians performing the debridements were blinded to group assignment. Sixteen of the 18 patients (89%) in the treatment group completely healed and remained healed at a follow-up of 1-36 months (13.5 ± 10.1). Only one (10%) of the patients in the control group healed. The amputation rate was 12.5% in the treated group versus 40% in the control group (P < 0.001). The HBO patients were sufficiently improved to be discharged in 62 days, and 16 completely healed. Nine of ten of the control group had not healed 82 days later.
In a follow-up study in 1990, 62 of 80 patients (78%) received a course of HBO.81 Ninety-six percent of the HBO patients went on to heal versus 66% of the control group. The amputation rate in the HBO group was 4.8% versus 33% in the control group (P < 0.001). The incidence of amputation in the untreated group was essentially unchanged from a group of patients treated nearly 10 years earlier without the benefit of adjunctive HBO. There were no statistical differences in any of the groups relating to age, glycemic control, or diabetes complications.

In a recently reported study, individuals with diabetes with nonhealing foot ulcers were consecutively admitted to a hospital for treatment.82 They were randomly assigned to either an HBO group or a control group. Two individuals, one in each group, did not complete the protocol and were excluded from analyses. A total of 35 individuals received HBO. Three (8.6%) of them underwent major amputation (the outcome variable) versus eleven (33.3%) in the nonHBO group (P = 0.016). The relative risk for the treated group was 0.26 (95% CI 0.08–0.84). Multivariate analysis confirmed the protective role of HBO (odds ratio 0.084, P = 0.033, 95% CI 0.008–0.821) and indicated as negative prognostic determinants low ankle-brachial index values (odds ratio 1.715, P = 0.013, 95% CI 1.121– 2.626) and high Wagner grade (odds ratio 11.199, P = 0.022, 95% CI 1.406–89.146).

To our knowledge, there has been only one double-blind, prospective, randomized study investigating the utility of HBO, which was performed in nondiabetic patients with chronic leg wounds.83 Individuals receiving HBO had a 35.7% (SD ± 17%) reduction in wound size at 6 weeks compared with 2.7% (SD ± 11%) in control subjects (P < 0.001).These studies indicate that HBO is an effective method for treating diabetic foot wounds in carefully selected cases of lower extremity lesions. They support the recommendation that HBO should be considered as an adjunct to wound healing and as part of multidisciplinary wound care. Additional studies to further define the role of HBO are underway.

One such study, funded by the American Diabetes Association, is in progress at our institution.84 This study will employ a prospective, randomized, placebo-controlled, double-blind design. All patients will receive standard wound care, which includes but is not limited to revascularization, offloading, glycemic control, infection control, debridements, and education and lifestyle modification. In addition, patients will be randomized into two groups: the treatment group (HBO) and the control group (no HBO). Both groups will receive treatment at 2.4 ATA (45 fsw) for a period of 100 minutes. The HBO group will be receiving 100% oxygen during the breathing periods.

The control patients will be exposed to the same hyperbaric environment, but will breathe a gas mixture equivalent to breathing air on the surface. We hypothesize that a defined course of intermittent increased tissue concentrations of oxygen will result in: 1) reduction in amputation rate; 2) increase in number of wounds that are completely healed; and 3) more rapid healing rates. The study will also evaluate whether there are specific subgroups of patients with diabetic wounds who will benefit most from HBO. This patient population will be analyzed according to age, objective evidence of adequacy of limb perfusion (severely compromised, moderately compromised, and preserved), presence or absence of peripheral neuropathy, and glycemic control.

1Diabetes 1996 Vital Statistics. Alexandria, Va., American Diabetes Association, 1996.
3Block P: The diabetic foot ulcer: a complex problem with a simple treatment approach. Milit Med 146:644-46, 1981.
4Knightom DR, Hunt TK, Scheunstuhl H, Callow AD, O’Donnell TF: Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science 221:1283-85, 1983.
5St. Anthony’s DRG Guidebook, Reston, Va., St. Anthony Publishing Co., 1995.
6Mackey WC, McCullough JL, Conlon TP, Shepard AD, Deterling RA: The cost of surgery for limb-threatening ischemia. Surgery 99:26-35, 1986.
7Ebskov B, Josephsen P: Incidence of reamputation and death after gangrene of the lower extremity. Prosthet Orthotics Inter 4:77-80, 1980.
8Couch NP, David JK, Tilney NL, Crane C: Natural history of the leg amputee. Am J Surg 133:469-73, 1977.
9Gibbons GW, Marcaccio EJ Jr, Burgess AM, Pomposelli FB Jr, Freeman DV, Campbell DR, Miller A, LoGerfo FW: Improved quality of diabetic footcare, 1984 vs. 1990. Arch Surg 128:576-81, 1993.
10Kihn RB, Warren R, Beebe GW: The geriatric amputee. Am J Surg 176:305-14, 1972.
11Ciani P, Petrone G, Drager S, Lueders H, Lee H, Shapiro R: Salvage of the problem wound and potential amputation with wound care and adjunctive hyperbaric oxygen therapy: an economic analysis. J Hyperbaric Med 3:127-41, 1988.
12U.S. Department of Health and Human Services: Healthy People 2000: National Health Promotion and Disease Prevention Objectives. Washington, D.C., Government Printing Office, 1991, p. 73-177, DHHS publ. No. 95-50213.
13Wheen L: The effectiveness and cost of oxygen therapy for diabetic foot wounds. SPUMS Journal 24:182-90, 1994.
14Edmonds ME, Blundell MP, Morris ME, Thomas EM, Cotton LT, Watkins PJ: Improved survival of the diabetic foot: the role of the specialized foot clinic. Q J Med 60:763-71, 1986.
15Wyss CR, Robertson C, Matsen FA, Love SJ, Harrington RM: Relationship between transcutaneous oxygen tension, ankle blood pressure, and clinical outcome of vascular surgery in diabetic and nondiabetic patients. Surgery 101:56-62, 1987.
16Zamboni WA, Roth AC, Russell RC, Nemiroff PM, Casas L, Smoot EC: The effect of acute hyperbaric oxygen therapy on axial pattern flap survival when administered during and after total ischemia. J Reconstr Microsurg 5:343-47, 1989.
17Aagenaes O, Moe H: Light- and electron-microscope study of skin capillaries of the diabetic. Diabetes 10:253-59, 1961.
18Arenson DJ, Sherwood CF, Wilson RC: Neuropathy, angiopathy, and sepsis in the diabetic foot: part 2: angiography. JAPA 71:661-65, 1981.
19McMillan DE, Breithaupt DL, Rosenau W, Lee JC, Forsham PH: Forearm skin capillaries of diabetic, potential diabetic and nondiabetic subjects: changes seen by light microscopy. Diabetes 15:251-57, 1966.
20Frederick HHR, Tucker WR, Schwartz TB: Observations on small blood vessels of skin in normal and in diabetic subjects. Diabetes 15:233-49, 1966.
21Vracko R, Strandness DR Jr: Basal lamina of abdominal skeletal muscle capillaries in diabetics and nondiabetics. Circulation 35:690-700, 1967.
22Joseph WS, Lefrock JL: The pathogenesis of the diabetic foot: infections, immunopathy, angiopathy, and neuropathy. J Foot Surg 26 (Suppl 1): S7-S11, 1987.
23Pecoraro RE: The nonhealing diabetic ulcer: major cause for limb loss. Prog Clin Biol Res 365:27-43, 1991.
24Knighton DR, Fylling CP, Fiegel VD, Cerra F: Amputation prevention in an independently reviewed at-risk diabetic population using a comprehensive wound care protocol. Am J Surg 160:466-71, 1990.
25Cianci P, Hunt TK: Adjunctive hyperbaric oxygen therapy in the treatment of diabetic wounds of the foot. In The Diabetic Foot. Fifth ed. Levin ME, O’Neal LW, Bowker JH, Eds. St. Louis, Mo., Mosby Year Book, 1993, p. 305-19.
26Pai MP, Hunt TK: Effect of varying oxygen tensions on healing of open wounds. Surg Gynecol Obstet 135:756-58, 1972.
27Medawar PB: The cultivation of adult mammalian skin epithelium. Q J Micro Sci 89:187-96, 1948.
28Mader JT, Brown GI, Guckian JC, Wells CH, Reinarz JA: A mechanism for the amelioration by hyperbaric oxygen of experimental staphylococcal osteomyelitis in rabbits. J Infect Dis 142:915-22, 1980.
29Chang N, Mathes SJ: Comparison of the effect of bacterial inoculation in musculocutaneous and random-pattern flaps. Plast Reconstr Surg 70:1-10, 1982.
30Gottrup F, Firmin R, Hunt TK, Mathes SJ: The dynamic properties of tissue oxygen in healing flaps. Surgery 95:527-36, 1984.
31Johnson K, Hunt TK, Mathes SJ: Effect of environmental oxygen in bacterial-induced tissue necrosis in flaps. Surg Forum 35:591-98, 1984.
32Pecoraro RE, Ahroni JH, Boyko EJ, Stensel VL: Chronology and determinants of tissue repair in diabetic lower extremity ulcers. Diabetes 40:1305-13, 1991.
33Hunt TK: The physiology of wound healing. Ann Emerg Med 17:1265-73, 1988.
34Knighton DR, Halliday B, Hunt TK: Oxygen as an antibiotic: the effect of inspired oxygen on infection. Arch Surg 119:199-204, 1984.
35Rohr S, Brisson Ch, Totl F, Aysoy C, Schneider F, Cazenave JP, Tempe JD: Effect of hyperbaric oxygen on angiogenesis in rats. In Proceedings of the Joint Meeting on Diving and Hyperbaric Medicine. Schmutz J, Wendling J, Eds. Basel, Switzerland, Foundation for Hyperbaric Medicine, 1992, p. 112-14.
36Marx RE, Ehler WJ, Tayapongsak, P, Pierce LW: Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg 160:519-24, 1990.
37Cotto-Cumba C, Velez E, Velu SS, Britten J, Myers RAM: Transcutaneous oxygen measurements in normal subjects using topical HBO control module. Undersea Baromed Res 18 (Suppl): 109, 1991.
38Leslie CA, Sapico FL, Vinunas VJ, Adkins RH: Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers. Diabetes Care 11:111-15, 1988.
39Davis JC: Refractory osteomyelitis. In Problem Wounds: The Role of Oxygen. Davis JC, Hunt TK, Eds. New York, Elsevier, 1988, p. 125-42.
40Boerema I, Meyne NG, Brummelkamp WH, Bouma S, Mensch MH, Kamermans F, Hanf MS, Aalderen WV: Life without blood: a study of the influence of high atmospheric pressure and hypothermia on dilution of blood. J Cardiovasc Surg 1:133-46, 1960.
41Brummelkamp WH, Hoogendijk J, Boerema I: Treatment of anaerobic infections (clostridia myosititis) by drenching the tissues with oxygen under high atmospheric pressure. Surgery 49:299-302, 1961.
42Goodman MW, Workman RP: Oxygen-breathing approach of treatment of decompression sickness in divers and aviators. BuShips Project SFO110606, Task 11513-2, Research Report 5-65. Washington D.C., Bureau of Medicine and Surgery, 1965.
43Kindwall EP: Carbon monoxide and cyanide poisoning. Hyperbar Oxygen Rev 1:115-21, 1980.
44Yarbrough OB, Behnke AR: The treatment of compressed air illness utilizing oxygen. J Indus Hygiene Toxicol 21:6, 1939.
45Hart GB, Lamb RC, Strauss MB: Gas gangrene: 2 parts. J Trauma 23:991-1000, 1983.
46Heimbach RD: Gas gangrene: review and update. Hyperbar Oxygen Rev 1:41-46, 1980.
47Skyhar MJ, Hargens AR, Strauss MB, Gershuni DH, Hart GB, Akeson WH: Hyperbaric oxygen reduces edema and necrosis of skeletal muscle in compartment syndromes associated with hemorrhagic hypotension. J Bone Joint Surg 68:1218-24, 1986.
48Strauss MB, Hart GB: Crush injury and the role of hyperbaric oxygen. Top Emerg Med 6:9-24, 1984.
49Strauss MB, Hargens AR, Gershuni DH, Greenberg DA, Crenshaw AG, Hart GB, Akeson WH: Reduction of skeletal muscle necrosis using intermittent hyperbaric oxygen in a model compartment syndrome. J Bone Joint Surg 65:656-62, 1983.
50Davis JC, Hunt TK: Problem Wounds: The Role of Oxygen. New York, Elsevier, 1988.
51Bakker DJ: Pure and mixed aerobic and anaerobic soft tissue infections. Hyperbar Oxygen Rev 6:65-96, 1985.
52Gozal D, Ziser A, Shupak A, Ariel A, Melamed Y: Necrotizing fasciitis. Arch Surg 121:233-35, 1986.
53Riseman JA, Zamboni WA, Curtis A, Graham DR, Konrad HR, Ross DS: Hyperbaric oxygen therapy for necrotizing fasciitis reduces mortality and the need for debridements. Surgery 108:847-50, 1990.
54Davis JC, Heckman JD, DeLee JC, Buckwold FJ: Chronic nonhematogenous osteomyelitis treated with adjuvant hyperbaric oxygen. J Bone Joint Surg 68:1210-17, 1986.
55Davis JC: Hyperbaric oxygen therapy. J Intens Care Med 4:55-57, 1989.
56Morrey BF, Dunn JM, Heimbach RD, Davis J: Hyperbaric oxygen and chronic osteomyelitis. Clin Orthop 144:121-27, 1979.
57Slack WJ, Thomas DA, Perrins JD: Hyperbaric oxygenation in chronic osteomyelitis. Lancet 1: 1093-94, 1965.
58Myers RA, Marx RE: Use of hyperbaric oxygen in postradiation head and neck surgery. NCI Monographs 9:151-57, 1990.
59Kaelin CM, Im MJ, Myers RAM, Manson PN, Hoopes JE: The effects of hyperbaric oxygen on free flaps in rats. Arch Surg 125:607-609, 1990.
60Tan CM, Im MJ, Myers RA: Effects of hyperbaric oxygen and hyperbaric air on the survival of island skin flaps. Plast Reconstr Surg 73:27-30, 1984.
61Zatz A, Brenner BM: Pathogenesis of diabetic microangiopathy: the hemodynamic view. Am J Med 80:443-53, 1986.
62Cianci P, Lueders HW, Lee H, Shapiro R, Sexton J, Williams C, Green B: Adjunctive hyperbaric oxygen reduces the need for surgery in 40-80% burns. J Hyperbar Med 3:97-101, 1988.
63Cianci P, Lueders HW, Lee H, Shapiro RL, Sexton J, Williams C, Sato R: Adjunctive hyperbaric oxygen reduces length of hospitalization in thermal burns. J Burn Care Rehab 10:432-35, 1989.
64Cianci P, Williams C, Lueders H, Lee H, Shapiro R, Sexton J, Sato R: Adjunctive hyperbaric oxygen in the treatment of thermal burns: an economic analysis. J Burn Care Rehab 11:140-43, 1990.
65Hart GB, O’Reilly RR, Broussard ND, Cave RH, Goodman DB, Yanda RL: Treatment of burns with hyperbaric oxygen. Surg Gynecol Obstet 139:693-96, 1974.
66Tibbles PM, Edelsberg JS: Medical progress: hyperbaric-oxygen therapy. N Engl J Med 334:1642-48, 1996.
67Davidson JD, Siddiqui A, Mustoe TA: Ischemic tissue oxygen capacitance after hyperbaric oxygen therapy- new physiologic concept. Undersea Hyperbar Med 23 (Suppl): 57, 1996.
68Thom SR: Hyperbaric oxygen therapy. J Int Care Med 4:58-74, 1989.
69Niinikoski J, Aho SJ: Combination of hyperbaric oxygen, surgery, and antibiotics in the treatment of clostridial gas gangrene. Infect Surg 23-37, 1983.
70Sheffield PJ: Tissue oxygenation measurements. In Problem Wounds: The Role of Oxygen. Davis JC, Hunt TK, Eds. New York, Elsevier, 1988.
71Davis JC: The use of adjuvant hyperbaric oxygen in the treatment of the diabetic foot. Clin Podiatr Med Surg 4:429-37, 1987.
72Cianci P, Petrone G, Green B: Adjunctive hyperbaric oxygen in the salvage of the diabetic foot. Undersea Baromed Res 18 (Suppl): 108, 1991.
73Oriani G, Sala C, Campagnoli P, Sacchi C, Meazza DT, Ronzio A, Montino O: Oxygen therapy and diabetic gangrene: a review of 10 years’ experience. In Proceedings of the Joint Meeting on Diving and Hyperbaric Medicine. Schmutz J, Wendling J, Eds. Basel, Switzerland, Foundations for Hyperbaric Medicine, 1992, p. 178-81.
74Gismondi A, Caione R. Sturda G: The "V Fazzi Hospital" diabetic foot wound care protocol: a cost-benefit evaluation. In Proceedings of the Joint Meeting on Diving and Hyperbaric Medicine. Schmutz J. Wendling J. Eds. Basel, Switzerland, Foundation for Hyperbaric Medicine, 1992, p. 1 82-84.
75Stone JA, Scott RG, Brill LR, Levine BD: The role of hyperbaric oxygen therapy in the treatment of the diabetic foot. Diabetes 44 (Suppl l): 71A, 1995.
76Wattel FE, Mathieu DM, Fossati P. Neviere RR, Coget JM: Hyperbaric oxygen in the treatment of diabetic foot lesions: search for healing predictive factors. J Hyperbar Med 6:263-68,1991.
77McDermott JE, Zell G: The Role of Hyperbaric Oxygen in the Management of Diabetic Ulcer. Presented at AOFAS Annual Meeting, Sun Valley, Idaho, Aug. 4,1989.
780riani G: Diabetic foot and hyperbaric oxygen therapy: a ten-year experience. J Hyperbar Med 7:213-21, 1992.
79Zamboni WA, Stephenson T: Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study. Undersea Hyperbar Med 22 (Suppl):11, 1995.
80Baroni GC, Porro T. Faglia E, Pizzi GL, Mastropasqua A, Oriani G. Pedesini G. Favales F: Hyperbaric oxygen in diabetic gangrene treatment. Diabetes Care 10:81-86,1987.
81Oriani G. Meazza D, Favales F. Pizzi GL, Aldeghi A, Faglia E: Hyperbaric oxygen therapy in diabetic gangrene. J Hyperbar Med 5:171-75, 1990.
82Faglia E, Favales F. Aldeghi A, Calia P. Quarantiello A, Oriani G. Michael M, Campagnoli P. Morabito A: Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer: a randomized study. Diabetes Care 19:1338-43,1996.
83Hammarlund C, Sundberg T: Hyperbaric oxygen reduced size of chronic leg ulcers: a randomized double-blind study. Plast Reconstr 5urg 93:82933, 1996.
84American Diabetes Association: The use of Hyperbaric Oxygen in the Treatment of Diabetic Wounds. Clinical Research Grant awarded May 1995.

Jeffrey A. Stone, DO, MPH, is the associate medical director in the Hyperbaric Medicine Department and medical director of the Aerospace Medicine Program at the Institute for Exercise and Environmental Medicine at Presbyterian Hospital of Dallas, in Texas. Paul Cianci, MD, FACP, is the director of the Department of Hyperbaric Medicine at Brookside Hospital in San Pablo, Calif., and the John Muir Medical Center in Walnut Creek, Calif.

For those interested in receiving HBOT that may have difficulty with financing the treatments, we have people that can give advice on fund-raising. The previous case studies are only a glimpse of the hundreds of people which have received HBOT at the Richmond Hyperbaric Center for a variety of conditions with favorable outcomes. Please contact us for more information on a particular condition which may benefit from hyperbaric oxygen therapy.

The Richmond Hyperbaric Health Center has engaged in scientific research projects including a pilot study on the treatment of RSD/CRPS. We would like to pursue future research studies as well and are open to any inquiries about the use of  HBOT  for researching various conditions.

back to top

Richmond Hyperbaric About Us | Site Map | Privacy Policy | Contact Us | ©1999 - 2013 Richmond Hyperbaric Health Center
This website is best viewed in IE 7.0 and Firefox 3.5.2 (Display Setting 1280 x 800 pixels)